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RECOMBINANT ANTIGEN MSPlA FROM 
ANAPLASMA MARGINALE TO REDUCE 
INFECTIONS IN TICKS, VACCINE 
COMPOSITIONS AND METHODS OF USE 
2 
immunity to A. marginale infection [20, 21, 22, 26]. See also 
U.S. Pat. No. 10/002,636, incorporated herein by reference. 
Recently, we demonstrated that infection of A. marginale 
for cultured tick cells was inhibited by antibodies against 
CROSS REFERENCE TO RELATED 
APPLICATION 
5 recombinant MSPla [23, 24]. While antisera from cattle 
naturally infected with A. marginale did not inhibit A. 
marginale infection, antibodies produced in rabbits and 
cattle immunized with the recombinant MSPla effected This application is a continuation-in part of prior filed, 
copending U.S. patent application Ser. No. 10/002,636, filed 10 
Oct. 26, 2001 which claims the benefit of U.S. provisional 
patent application Ser. No. 60/244,333, filed Oct. 30, 2000, 
both of which are hereby incorporated by reference. 
inhibition of A. marginale infection for the cultured tick cells 
[24]. This inhibitory effect has also been demonstrated using 
antibodies against a synthetic MSPla repeated peptide, and 
this data provided additional evidence that MSPla plays a 
role in adhesion of A. marginale to tick cells [15]. 
Vaccination is the most efficient and economical method BACKGROUND OF THE INVENTION 
1. Technical Field 
The present invention relates to recombinant Anaplasma 
marginale major surface protein (MSP)la, related vaccines 
and methods useful to reduce infections in ticks and affect 
the biological transmission of the pathogen of the species A. 
marginale. 
15 for control of anaplasmosis, and development of effective 
vaccines has been a priority of the cattle industry worldwide 
[9]. Infected bovine erythrocytes have been the only source 
of vaccine antigen until recently when a tick cell culture 
system was developed for propagation of A. marginale and 
20 provides an alternative antigen source. The cell culture-
derived A. marginale is currently being tested as antigen for 
use in vaccine development [20, 22]. See also U.S. Pat. No. 
5,869,335, incorporated herein by reference. 
2. Background 
Thus far, vaccines using erythrocyte or cell culture-
derived antigens have effected reduction of clinical disease 
but have not prevented infection of cattle [9, 20, 22, 25, 27, 
28, 37]. Also, antibodies in cattle immunized with 
erythrocyte-derived A. marginale have not caused reduction 
of A. marginale infections in ticks [7]. 
The desired result of a vaccine for the control of anaplas-
mosis is to have a protection effect on the multiplication of 
A. marginale in the bovine host and a blocking effect on the 
transmission of the pathogen by the tick vector. Existing 
Anaplasmosis is a tick-borne disease of cattle caused by 
Anaplasma marginale (Rickettsiales: Anaplasmataceae ). 25 
The only known site of development of A. marginale in 
cattle is within erythrocytes [1]. The number of infected 
erythrocytes increases logarithmically during infection and 
removal of infected erythrocytes by phagocytic cells of the 
reticuloendothelial system often results in development of 30 
anemia and icterus without hemoglobinemia and hemoglo-
binuria [2]. While mechanical transmission of A. marginale 
occurs when infected blood is transferred from infected to 
susceptible animals by biting flies or blood-contaminated 
fomites, biological transmission is effected by feeding ticks. 
Approximately 20 species of ticks have been incriminated as 
vectors worldwide [3, 4]. Cattle that recover from acute 
infection remain persistently infected and develop life-long 
immunity against clinical disease, but they serve as reser-
voirs of infection for mechanical and/or biological transmis-
sion by ticks. 
35 vaccines and experimental vaccines, however, including 
formulations using the recombinant MSPla, the MSPl 
complex and partially purified parasites from infected eryth-
rocytes and cultured tick cells (see U.S. Pat. Nos. 5,549,898; 
5,869,335 and 10/002,636 incorporated herein by reference) 
The development of A. marginale in ticks is complex and 
coordinated with the tick feeding cycle [5, 6, 8]. In the cycle 
40 have not demonstrated any effect on the infection of the tick 
vector by the pathogen. Therefore, it is desirable to develop 
vaccines against anaplasmosis with protection effect on the 
multiplication of A. marginale in the bovine host and an 
of A. marginale that was described in male ticks transferred 
from infected to susceptible hosts, the first site of infection 45 
occurs in tick gut cells. After the ticks feed a second time, 
many other tick tissues become infected, including the 
salivary glands from where the rickettsiae are transmitted to 
cattle during feeding. Male ticks become persistently 
infected with A. marginale and are able to transmit A. 50 
marginale to multiple hosts [6, 7, 8]. 
Major surface protein (MSP)la is one of six MSPs that 
have been described on A. marginale derived from bovine 
erythrocytes [9]. MSPla forms the MSPl complex with 
MSPlb [10, 11]. MSPla is encoded by a single gene, 55 
mspla, which is conserved during the multiplication of the 
bacterium in cattle and ticks [12, 13]. This protein is variable 
in molecular weight among geographic isolates because of 
varying numbers of tandem 28 or 29 amino acid repeats 
located in the amino terminal portion of the protein [11, 14, 60 
15]. MSPla was shown to be an adhesin for bovine eryth-
rocytes and for both native and cultured tick cells using 
recombinant£. coli expressing MSPla in microtiter hemag-
glutination and adhesion recovery assays and by microscopy 
[16, 17, 18]. Furthermore, MSPla was shown to effect 65 
infection and transmission of A. marginale by Dermacentor 
spp. ticks [19] and was also shown to be involved in bovine 
effect on the transmission of the pathogen by the tick vector. 
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 
skilled in the art from the following detailed description, 
taken in conjunction with the attached figures, wherein there 
is described the preferred embodiment of the invention, 
simply by way of illustration of the best mode contemplated 
for carrying out the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graphical illustration of the immune response 
against MSPla and MSPlb determined by Western blot 
analysis of sera derived from immunized cattle and controls 
generated in connection with the experimental results 
reported herein. 
FIG. 2 is a graphical illustration of the reduction in PCV 
achieved by various combinations of antigens and controls 
in connection with the experimental results reported herein. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Before explaining the present invention in detail, 1t 1s 
important to understand that the invention is not limited in 
US 6,979,451 Bl 
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DNA was extracted from 1 ml stored blood samples con-
taining infected bovine erythrocytes collected during high 
parasitemia employing 250 µL Tri Reagent (Sigma) and 
following manufacturer's recommendations. Extracted 
its application to the details of the embodiments and steps 
described herein. The invention is capable of other embodi-
ments and of being practiced or carried out in a variety of 
ways. It is to be understood that the phraseology and 
terminology employed herein is for the purpose of descrip-
tion and not of limitation. 
In accordance with the present invention there is provided 
a new vaccine against the rickettsial cattle pathogen A. 
marginale through the use of discrete recombinant MSPla 
and polypeptides derived from MSPla containing the immu-
noprotective and functional regions that are expressed in 
E.coli. In one aspect, only recombinant MSPla or immu-
noprotective and functional regions thereof are utilized as 
the antigenic component of the vaccine. In another aspect, 
recombinant MSPla or subunits thereof are utilized in 
combination with other antigen preparations, particularly 
antigen preparations derived from A. marginale-infected 
cultured tick IDES cells. Another aspect of the present 
invention relates to recombinantA. marginale major surface 
protein (MSP)la, related vaccines and methods useful to 
reduce infections in ticks and affect the biological transmis-
sion of the pathogen of the species A. marginale. 
5 DNA was resuspended in 100 µL water. The mspla gene 
was amplified from 1 µL DNA by PCR using 10 pmol of 
each primer MSPlaP: 5'GCATTACAACGCAACGCT-
TGAG3' (SEQ. ID NO: 1) and MSP1a3: 5'GCTTTACGC-
CGCCGCCTGCGCC3' (SEQ. ID NO: 2) in a 50-µL volume 
10 PCR employing the Access RT-PCR system (Promega). 
Reactions were performed in an automated DNA thermal 
cycler (Eppendort) for 35 cycles. After an initial denatur-
ation step of 30 sec at 94° C., each cycle consisted of a 
denaturing step of 30 sec at 94° C. and an annealing-
15 extension step of 2.5 min at 68° C. The program ended by 
storing the reactions at 4 ° C. PCR products were electro-
phoresed on 1 % agarose gels to check the size of amplified 
fragments. The amplified fragments were resin purified from 
PCR reactions (Wizard Promega) and cloned into pGEM-T 
20 vector (Promega) for sequencing both strands (Core 
Sequencing Facility, Department of Biochemistry and 
Molecular Biology, Noble Research Center, Oklahoma State 
University). 
MSPla and MSPlb are isolated from A. marginale initial 
bodies as a complex of two noncovalently linked, antigeni-
cally distinct polypeptides. It is possible that the association 
between MSPla and MSPlb in the surface protein complex 
allows the parasite to more effectively bind to erythrocyte 25 
and/or tick cell components. MSPla could be the essential 
subunit in the recognition of the tick cell receptor, while the 
binding to the erythrocyte receptor could be mediated pri-
marily by MSPlb or by both protein subunits through the 
binding of distinct erythrocyte components. Additionally, 
the association between MSPla and MSPlb could stabilize 30 
and/or properly conform the MSPl complex [29]. 
MSPla is encoded by a single monocystronic gene, 
mspla, which is polymorphic among geographical isolates 
of A. marginale [30, 31, 32]. A. marginale isolates differ in 
the number of 28-29 amino acids tandem repeats within the 35 
MSPla polypeptide [31, 32], which contain a neutralization-
sensitive epitope [33, 31]. However, the sequence of mspla 
does not change during the multiplication of the parasite in 
the bovine host and the tick vector. The second MSPl 
subunit, MSPlb, is encoded by at least two monocystronic 40 
genes, mspl~l and msp1~2 [34]. These loci are polymor-
phic between and within populations of A. marginale from 
different geographical regions and life cycle stages but 
conserve a high degree of similarity. Sequence diversity is 
mainly due to point mutations in variable regions, perhaps 45 
due to selective immune pressure. The genetic structure of 
mspla together with the vital function of codified polypep-
tides permits the inclusion of recombinant MSPla 
polypeptides, or its functional domains, in vaccine formu-
lations against A. marginale. 50 
The experiments described and examples provided here-
inafter demonstrate that cattle immunized with recombinant 
MSPla alone or in combination with tick cell culture 
derived A. marginale are unexpectedly better protected 
against A. marginale infection as demonstrated by a lower 
reduction in packed cell volume (PCV) and lower peak 55 
parasitemia (PPE) than cattle immunized with the MSPl 
complex, a combination of uncomplexed MSPla and 
MSPlb surface protein antigens, the MSPlb antigen alone, 
cell culture derived A. marginale, or cell culture derived A. 
marginale combined with MSPlb. Indeed, only erythrocyte- 60 
derived A. marginale appears to confer like protection. 
EXAMPLE 1 
Preparation of Recombinant E. coli Expressing 
MSPla and Preparation of Antigen 65 
The mspla gene was cloned by PCR from the Oklahoma 
isolate of A. marginale derived from infected erythrocytes. 
For high level expression of MSPla, mspla coding 
region was amplified from perl (mspla in pGEM-T vector) 
plasmid DNA by PCR using the primers 5'CCGCTC-
GAGATGTTAGCGGAGTATGTGTCC3' (SEQ. ID NO: 3) 
and 5'GAAGATCTCGCCGCCGCCTGCGCC3' (SEQ. ID 
NO: 4). The mspla amplification product was digested with 
XhoI and Bglll and inserted into the cloning site of pFLAG-
CTC expression vector (Sigma). Recombinant plasmid was 
named pFLCla. In this construct, the inserted gene is under 
the control of the inducible tac promoter and yield full-
length MSPla polypeptide, with a C-terminal fusion of a 
FLAG marker octapeptide. The fidelity and orientation of 
the construct was verified by sequencing. For expression of 
MSPla recombinant polypeptides, pFLCla expression plas-
mid was transformed into E. coli K-12 (strain JM109). 
Transformed E. coli strains were inoculated in LB contain-
ing 50 µg/ml Ampicillin and 0.4% glucose. Cultures were 
grown at 37° C. to OD 6 oonm=0.4. IPTG was then added to 
0.5 mM final concentration, and incubation continued dur-
ing 4 h, for induction MSPla expression. Cells were col-
lected by centrifugation and membranes extracted after 
sonication and centrifugation. MSPlb was cloned, 
expressed and purified in a similar way. Doses of 5 ml 
containing 100 µg recombinant antigens were used for 
vaccination in subsequent studies. 
EXAMPLE 2 
Analysis of the Protective Capacity of Vaccine 
Preparations Containing Recombinant MSPla 
1. Propagation of Anaplasma marginale in tick cell culture 
and preparation of immunogen. The IDES (ATCC CRL 
11973) tick cell line derived from embryos of Ixodes 
scapularis was maintained at 31 ° C. in L-15B medium, 
pH 7.2, supplemented with 5% heat inactivated fetal 
bovine serum (FBS; Sigma, USA), 10% tryptose phos-
phate broth (Difeo, USA) and 0.1 % bovine lipoprotein 
concentrate (ICN, USA). Cultures were grown in 25-cm2 
plastic flasks (Nunc, Rosekilde, Denmark) with 5 ml of 
medium, and the medium was replaced weekly. The cells 
were subcultured at 1:5 to 1:20, and the cells became 
tightly adherent to the culture substrate and multiplied 
with a population doubling time of 3 to 5 days to a density 
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of about 5xl06 cells/ml. Nearly confluent monolayers 
from each passage were collected and stored in liquid 
nitrogen in medium with 10% DMSO. 
Tick cell cultures infected with the Oklahoma isolate of A. 
marginale were propagated. Terminal cell cultures were 5 
harvested, the cells centrifuged, and the contents of each T25 
flask was resuspended in 1 ml PBS and stored at - 70° C. 
until used as antigen for immunogen doses. The antigen 
aliquots were thawed, pooled and a sample was taken and 
tested by indirect ELISA The cell culture-derived antigen 10 
was inactivated with beta propiolactone (BPL) and the 
volume was adjusted to 5 ml so that each dose contained 
approximately 2xl010 A. marginale. 
2. Preparation of A. marginale antigen from bovine eryth-
rocytes. Two susceptible, splenectomized calves (PA432 15 
and PA433) were each inoculated with 2.5 ml blood 
stabilate ( 40% parasitemia) collected from a calf with the 
Virginia isolate of A. marginale. The calves were moni-
tored for infection by examination of stained blood 
smears. Blood was collected from PA432 at parasitemias 20 
of 13.6% and 32.7% and from PA433 at parasitemias of 
12.2% and 12.9%. After each collection, the erythrocytes 
were washed 3 times in PBS, each time removing the 
buffy coat. The erythrocytes were frozen at - 70° C. 1: 1 in 
RPMI 1640 cell culture medium until used as antigen for 25 
the immunization studies. The frozen erythrocyte antigen 
was thawed, washed in PBS, and centrifuged. The result-
ing pellet was washed to remove the hemoglobin, after 
which the antigen was pooled and inactivated with 
~-propiolactone (BPL). An aliquot was tested by ELISA 30 
as described previously for the erythrocyte antigen prepa-
ration using a known erythrocyte standard. Doses (5 ml) 
were prepared that contained approximately 2xl010 A. 
marginale. 
3. Experimental design. Fifty, 16-month month old Angus 35 
cattle were randomly assigned into ten groups of five 
cattle each that were immunized with various antigens as 
follows. (1) MSPl complex, (2) MSPla and MSPlb, (3) 
MSPla, (4) MSPlb, (5) cell culture-derivedA. marginale, 
(6) cell culture-derived A. marginale and MSPla, (7) cell 40 
culture-derived A. marginale and MSPlb, (8) erythrocyte-
derived A. marginale, (9) uninfected IDES tick cells and 
(10) adjuvant only. 
4. Immunizations. All cattle were immunized 3 times by 
subcutaneous injection of the antigen at weeks 1, 4 and 6. 45 
Each antigen dose was 5 ml in volume and contained an 
antigen in the adjuvant, XTEND® III (Grand 
Laboratories, Larchwood, Iowa). All cattle were 
challenge-exposed 10 weeks after the last immunization 
with lx107 A. marginale infected erythrocytes collected 50 
from a calf experimentally infected with the Oklahoma 
isolate of A. marginale. Blood of the immunized and 
control cattle was monitored for infection with A. mar-
ginale by microscopic examination of blood smears and 
hematology was done daily after the onset of infection. 55 
Parameters evaluated in cattle included determination of 
the peak percent infected erythrocytes (PPE), percent 
reduction in the packed cell volume (PCV), and the 
prepatent period (days) determined from the day of 
challenge-exposure to the onset of infection. 60 
5. Collection of blood and serum samples. Whole blood was 
collected in vacutainer tubes containing EDTA and used 
for preparation of stained blood smears for light micros-
copy and for determination of the PCV. Serum samples 
were collected from each animal before immunization, 65 
weekly until the cattle were challenge-exposed and daily 
after cattle developed parasitemia as a result of challenge-
6 
exposure. Serum samples were stored at - 70° C. until 
tested by competitive ELISA and Western blots. 
6. Characterization of the immune response in vaccinated 
cattle by competitive ELISA and Western blots. Antibody 
responses of all immunized and control cattle at two 
weeks after the last immunization to MSPla, MSPlb and 
MSP5 were determined using ELISAs specific for detec-
tion of antibodies to each of these MSPs. Antibody 
responses of all immunized and control cattle at two 
weeks after the last immunization to MSPla and MSPlb 
were also analyzed by Western blot. One hundred micro-
grams of recombinant MSPla or MSPlb were loaded in 
an 8% polyacrylamide gel. SDS-PAGE gels were trans-
ferred to a nitrocellulose membrane. The membrane was 
blocked with 5% skim milk for 1 hr at room temperature. 
Sera from immunized cattle was diluted 1:200 in TBS. 
Serum from an uninfected bovine was included as a 
negative control. All sera were incubated with the mem-
brane for 1 hr at room temperature using a Mini-Protean 
II Multi-screen (BioRad, USA). The membrane was 
washed 3 times with TEST and incubated for 1 hr at room 
temperature with goat anti-rabbit IgG alkaline phos-
phatase conjugate (KPL, USA) diluted 1:10,000. The 
membrane was washed again and the color developed 
using Sigma Fast BCIP/NBT alkaline phosphatase sub-
strate tablets. The membrane was then examined for 
recognition of the bands corresponding to MSPla and 
MSPlb. 
7. Statistical analysis. For the analysis of results from the 
immunization experiment, pairwise comparisons 
(Student's t test) were conducted to compare results 
between cattle immunized with antigen preparations and 
the controls. Parameters analyzed included the prepatent 
period (days), the peak percent parasitized erythrocytes 
(PPE) and the percent reduction in the packed cell volume 
(PCV). Mean antibody levels were compared using an 
ANOVA test. 
8. Results. Antibody titers against MSPla, MSPlb and 
MSP5 in immunized cattle peaked two weeks after the 
last immunization. The immune response against MSPla, 
MSPlb and MSP5 was analyzed by Western blot. Cattle 
immunized with recombinant antigen preparations 
responded to recombinant proteins included on each 
preparation (FIG. 1). Cattle immunized with tick cell 
derived A. marginale antigens and with infected 
erythrocytes-derived antigens recognized primarily 
MSPlb or MSPla, respectively (FIG. 1). 
Protection was evaluated using the reduction in PCV, the 
PPE and the prepatent period. No differences were observed 
in the prepatent period. The PPE was reduced in cattle 
immunized with MSPla, MSPlb, the combination of 
recombinant antigens with infected tick cells-derived anti-
gens and in animals immunized with infected erythrocytes-
derived antigens as shown in Table 1. 
TABLE 1 
Peak Parasitemia (%) 
Group Ave SD p 
MSPl 5.5 2.8 0.13 
la+ lb 6.0 1.6 0.14 
la 4.8 0.6 0.03 
lb 3.9 1.0 0.01 
TC 4.1 2.3 0.03 
la+ TC 4.7 1.4 0.03 
lb+ TC 3.9 0.8 0.01 
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TABLE 1-continued 
Peak Parasitemia (%) 
Ave SD 
2.7 1.1 
5.5 1.4 
7.4 2.3 
p 5 
0.004 
0.08 
10 
The reduction in PCV, associated with clinical signs, was 
significantly reduced in cattle immunized with MSPla com-
bined with infected tick cell-derived antigens and in cattle 
immunized with erythrocyte-derived antigens (See FIG. 2, 
wherein Reduction PCV=[(Ave Start PCV-Lowest PCV)/ 15 
Start PCV]xlO0). 
The results of these experiments demonstrated that: 
a. Cattle immunized with infected tick cell-derived anti-
gens had a preferential recognition for MSPlb while 
cattle immunized with erythrocyte-derived antigens 20 
showed a bias toward MSPla. The bias in the antibody 
response against MSPla or MSPlb in cattle immunized 
with A. marginale antigens from IDES tick cells or 
bovine erythrocytes suggests that the MSPl complex 
exposure on the surface of parasites may vary during 25 
multiplication on the tick and mammalian hosts; 
b. The immunization with the MSPl complex or with 
MSPla and MSPlb together did not protect cattle after 
challenge with A. marginale despite that cattle 
responded to both antigens; and 30 
c. Cattle with a predominant immune response against 
MSPla (groups immunized with MSPla, MSPla plus 
infected tick cell-derived antigens and infected 
erythrocyte-derived antigens) were protected againstA. 
marginale infection as demonstrated by the lower 35 
reduction in PCV. 
8 
cycler (Eppendorf MASTERCYCLER® personal, USA) 
for 35 cycles. After an initial denaturation step of 30 sec 
at 94° C., each cycle consisted of a denaturing step of 30 
sec at 94° C. and an annealing-extension step of 2.5 min 
at 68° C. The program ended by storing the reactions at 
4 ° C. The primers introduced an ATG initiation codon and 
Eco RI and Bgl II restriction sites for cloning into the 
pFLAG-CTC expression vector (Sigma). The resulting 
plasmid pAF0Rl was transformed into E. coli JM109 and 
induced for expression of mutant MSPla as previously 
reported for MSPla [14]. For the expression of MSPla 
(Oklahoma isolate mspla clone perl [14]) tandem 
repeats in E. coli, this region was amplified using oligo-
nucleotide primers RNOKBSS (5'-GAGATCTGCT 
GATGGCTCGTCAGCGGG-3') (SEQ. ID NO: 7) and 
RNOKBS3 (5'-GGTCGACCCTGATTGAGACGATGT 
ACTGGCC-3') (SEQ. ID NO: 8). The PCR was con-
ducted as previously described but with amplification 
cycles consisting of a denaturing step of 30 sec at 94° C., 
an annealing step of 30 sec at 58° C. and an extension step 
of 1 min at 68° C. The 5' and 3' amplification primers 
contained Bgl II and Sal I restriction sites, respectively, 
for cloning into pFLClb [14] for expression in E. coli as 
a fusion peptide to the COOR-terminus of MSPlb (locus 
~1, Oklahoma isolate). The resulting plasmid pFlbRNO4 
was transformed into E. coli JM109 and induced for 
expression of mutant MSPlb>MSPla-repeats protein as 
previously reported for MSPlb [14]. All constructs were 
sequenced at the Core Sequencing Facility, Department of 
Biochemistry and Molecular Biology, Noble Research 
Center, Oklahoma State University using ABI Prism dye 
terminator cycle sequencing protocols developed by 
Applied Biosystems (Perkin-Elmer Corp., Foster City 
Calif.). 
Expression of recombinant mutant proteins was assayed 
by SDS-PAGE, Western blot or live-cell immunofluores-
cence assay as previously reported [35]. The hemagglutina-
tion of bovine erythrocytes and adhesion to cultured IDES 
tick cells of recombinant E. coli expressing the wild type and 
It can thus be appreciated that the utilization of recom-
binant MSPla in vaccines provides an advantageous mecha-
nism to achieve resistance in cattle against A. marginale 
infection. Whereas erythrocyte-derived A. marginale is dis-
advantaged due to cost, difficulties in purifying antigen from 
bovine membranes, problems with preventing pathogen 
contamination and difficulties in standardization, recombi-
nant MSPla may be readily and cost effectively prepared in 
40 mutant proteins was evaluated in a microtitre hemaggluti-
nation and E. coli recovery adhesion assays, respectively, as 
reported [35]. 
a standardized, pure form free of bovine erythrocyte mem- 45 
branes and antigens that might result in formation of an 
immune response to bovine blood cells. 
EXAMPLE 3 
Function of MSPla Tandem Repeats in Adhesion 
to Host Cell Receptors 
50 
1. Construction, expression in E. coli and characterization of 
wild type MSPla and mutants. A MSPla (Oklahoma 55 
isolate mspla clone perl [14]) mutant lacking the tandem 
repeats was constructed by PCR. Oligonucleotide primers 
RIOR (5'-CCGAATTCCATGTTAGCGGCTAATTGGCG 
GCAAGAGATGCG-3') (SEQ. ID NO: 5) and 
MSP1a3BII (5'-CCAGATCTCTTTACGCCGCCGCC 60 
TGCGCC-3') (SEQ. ID NO: 6) were designed to amplify 
the mspla gene lacking 6 amino acids preceding the 
repeats and the tandem repeats in a 50 µl volume PCR (0.2 
µM each primer, 1.5 mM MgSO4 , 0.2 mM dNTP, 
lxAMV/Tfl reaction buffer, Su Tfl DNA polymerase) 65 
employing the Access RT-PCR system (Promega, USA). 
Reactions were performed in an automated DNA thermal 
2. Results. To study the function and structural organization 
of tandem repeated peptides in MSPla we selected a 
recent A. marginale field isolate from Oklahoma that is 
tick-transmissible and for which we have cloned and 
characterized MSPla and MSPlb. A recombinant mutant 
MSPla was constructed lacking the tandem repeated 
peptides and expressed in E. coli. The recombinant 
mutant protein was expressed at high levels and was 
secreted to the E. coli membrane as shown by live-cell 
immunofluorescence. Nevertheless, the adhesion to cul-
tured IDES tick cells of recombinant E. coli expressing 
the mutant protein was abolished when compared to the 
wild type MSPla (Table 2). To demonstrate that the 
MSPla repeats were not only necessary but sufficient to 
confer adhesion of recombinant E. coil to tick cells, we 
then constructed a chimeric protein containing the MSPla 
tandem repeated peptides fused to the COOR-terminus of 
the MSPlb. MSPlb did not confer an adhesive phenotype 
when expressed in E. coli (Table 3). However, E. coli 
expressing the chimeric protein adhered to cultured IDES 
tick cells at levels comparable to the wild type MSPla-
expressing E. coli (Table 3). 
The capacity of MSPla to hemagglutinate bovine eryth-
rocytes was also mediated by the tandem repeats. Recom-
binant E. coli expressing the MSPla lacking the tandem 
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repeats were unable to hemagglutinate bovine erythrocytes 
(Table 2) while the chimeric MSPlb>MSPla-repeats protein 
expressed in E. coli conferred to recombinant bacteria a 
higher hemagglutination capacity (Table 3) when compared 
to wild type MSPs. 
TABLE 2 
Hemagglutination of bovine erythrocytes and adhesion to cultured tick 
IDES cells by recombinant E. coli expressing A. marginale 
(Oklahoma isolate) MSPla wild type and mutant protein without repeats 
Plasmid carried by recombinant E. coli 
Relevant protein expressed 
No. of CFU (mean ± SD) 
recovered from IDES cells 
(N- 3) 
Average fold increase over 
p33 control 
P (Student's t-Test) 
Average fold decrease over 
MSPla (OK) 
P (Student's t-Test) 
Hemagglutination of bovine 
erythrocytes (N - 3)' 
pFLCla 
MSPla 
500 ± 141 
2 
0.05 
pAF0Rl 
MSPla-no 
repeats 
mutant 
14 ± 18 
36 
0.02 
0 
No 
p33 plasmid 
None None 
231 ± 129 0 
0 0 
ao, no hemagglutination; 1, weak hemagglutination; 2, moderate hemag-
glutination; 3, near maximum hemagglutination; 4, maximum hemaggluti-
nation [7]. 
TABLE 3 
Hemagglutination of bovine erythrocytes and adhesion to cultured IDES 
tick cells of E. coli expressing wild type MSPla or MS Pl b 
(Oklahoma isolate) and MSPlb > MSPla-repeats mutant proteins 
Plasmid carried by recombinant E. coli 
Relevant protein pFLCla pFLC1b2 PF1bRNO4 
expressed MSPla MSPlb MSPlb > MSPla-repeats 
No. of CFU recovered 975 ± 742 18 ± 17 530 ± 325 
from IDES cells 
(Ave ± SD) (N - 2) 
Average fold increase 54 29 
over pFLC1b2 
(MSPlb) 
Hemagglutination of 4 5 
bovine erythrocytes 
(N- 2)' 
aPlates were incubated for 2 hours at 40° C. and results scored essentially 
as reported by McGarey and Allred [7]: 0, no hemagglutination; 1, weak 
hemagglutination; 2, moderate hemagglutination; 3, near maximum 
hemagglutination; 4, maximum hemagglutination; 5, maximum hemagglu-
tination in 1 hour. 
10 
decrease in the symptoms of anaplasmosis includes preven-
tion of the reduction in the packed red cell volume and a 
decrease in percent parasitemia. Preferably, a protective 
response includes packed red cell volume change of 25% or 
5 less compared with control animals and/or a decrease in 
parasitemia to about 5 to 25% of the red blood cells or less 
depending on the conditions. Measurements of packed red 
cell volume and percent parasitemia are conducted using 
standard methods. Vaccine preparations are combined with 
10 physiologically acceptable carriers to form vaccines. The 
preferred physiologically acceptable carrier is an oil-based 
adjuvant. 
15 
Preferably, the inventive vaccine formulation is set to 
contain about 100 micrograms of recombinant antigens 
associated to E. coli membranes in an oil-based adjuvant 
such as XTEND® III (Grand Laboratories, Larchwood, 
Iowa). 
The vaccines may be administered by a variety of routes 
including intravenously, intraperitoneally, intramuscularly, 
20 and subcutaneously. The preferred route of administration is 
subcutaneous. The vaccine can be administered in a single 
dose or multiple doses until a protective effect is achieved. 
25 
Recombinant Antigen MSPla from Anaplasma 
marginale to Reduce Infections in Ticks, Vaccine 
Compositions and Methods of Use 
It has been discovered that the incorporation of recombi-
nant MSPla in vaccine formulations againstA. marginale in 
combination with infected IDES cells-derived antigens and/ 
30 or pathogen and tick-derived antigens would allow the 
development of vaccines against anaplasmosis with protec-
tion effect on the multiplication of A. marginale in the 
bovine host and an effect on the transmission of the pathogen 
by the tick vector. A. marginale Oklahoma isolate major 
35 surface protein la (mspla) gene (AY010247) is provided as 
SEQ. ID NO: 9, and major surface protein la (AAG29248) 
sequence listing is provided as SEQ. ID NO: 10. 
40 
45 
50 
1. Cattle Vaccination and Challenge 
Twenty Holstein cattle, 12 to 24 months old, were used for 
this study. These cattle were selected from 55 cattle used for 
a larger vaccine trial that were randomly assigned to two 
experimental groups of 20 cattle each and one group of 15 
control cattle in which Group 1 cattle were immunized with 
three isolates of A. marginale derived from tick cell culture 
(Virginia, Oklahoma and Oregon isolates) and 100 µg 
recombinant MSPla; Group 2 cattle were immunized with 
100 µg of recombinant MSPla; and cattle in Group 3 were 
left unvaccinated to serve as controls for natural infection 
conditions. 
Accordingly, it can be appreciated that subunits derived 
from MSPla are useful as well in the inventive vaccine 
compositions. The inclusion of MSPla region(s) effecting 
MSPla biological function could enhance the host immune 55 
response directed against relevant immunoprotective 
epitopes. 
It has been demonstrated that A. marginale infection 
levels in ticks fed on cattle immunized with E. coli mem-
branes and uninfected cultured IDES tick cell-derived anti-
gens were similar to the infection levels in ticks fed on 
non-immunized cattle. 
Ten immunized cattle were selected for this study based 
on detection of high antibody titers against recombinant 
MSPla. Of these ten cattle, 5 were chosen from Group 1 
(cattle 226, GT168, 242, 294, 141) and 5 were chosen from 
Group 3. Cattle GT165, GT155, 219, 248, GT152) for the 
non-immunized controls, ten cattle (214,210,245,251, 143, 
157, 247, 217, 166, 162) were randomly chosen out of the 
The preparation of vaccines utilizing as distinct antigenic 
components MSPla is easily accomplished using well 
known methods and techniques. The vaccine and/or antigen 60 
preparation is combined into a formulation in an amount 
effective to provide for a protective immune response 
against infection with A. marginale. A protective immune 
response againstA. marginale decreases the clinical signs of 
anaplasmosis. Clinical symptoms of anaplasmosis include a 65 
reduction in packed red cell volume of about 25 to 80% and 
parasitemia of the red blood cells of about 15 to 70%. A 
15 control cattle from the larger study. 
A. marginale antigens from infected IDES cells were 
prepared as described previously [20,22]. Recombinant 
MSPla was prepared by inducing the expression of the 
protein in E. coli [18]. The E. coli cells were then disrupted 
by sonication followed by centrifugation for separation of 
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soluble from membrane bound antigens. The resulting pellet 
that contained the MS Pl a in E. coli membranes was used for 
immunization. The total protein concentration was deter-
mined and the amount of recombinant MSPla was estimated 
from Western blots using affinity purified recombinant 
MSPla as standard [22]. 
Cattle were immunized at weeks 4 and 8 with a 5 ml dose 
containing the antigen in an oil-based adjuvant (Adjuvant 
XTEND® III Grand Laboratories, Larchwood, Iowa, USA) 
[20]. Cattle were challenge-exposed two weeks after the last 
immunization by intravenous administration of 1.7 ml 
infected blood containing 109 A. marginale. The challenge-
exposure blood was obtained from a splenectomized calf 
that was experimentally infected with the Virginia isolate of 
A. marginale (calf PA481, percent infected erythrocytes 
(PPE) of 10.4%, packed cell volume (PCV) of 31.5%). 
Parameters used for evaluation of cattle included determi-
nation of the PPE and PCV. Whole blood was collected in 
vacutainer tubes containing EDTA and used for preparation 
of stained blood smears for light microscopy and for deter-
mination of the PCV. Serum samples were collected from 
each animal upon purchase, at weeks 4 and 8 just prior to 
immunization, at week 10 and during tick feeding. Serum 
samples were stored at - 70° C. until tested by ELISA and 
Western blots for determination of MSPla antibody titers. 
2. Identification of Cattle with High Antibody Liters to 
MSPla, Tick Feeding Studies and Determination of A. 
marginale Infection Levels in Tick Salivary Glands. 
Serum samples collected from cattle two weeks after the 
last immunization were analyzed as described previously by 
ELISA and Western blots for recognition of recombinant 
MSPla [22]. Ten immunized animals with the highest titers 
against MSPla by Western blot were selected from groups 
1 and 2 (5 animals from each). Ten control animals from 
group 3 were randomly selected and sera from these cattle 
were proven to be negative for MSPla antibodies by West-
ern blot. 
5 
10 
15 
20 
25 
30 
35 
Each of the 20 cattle were infested with 60 male D. 
variabilis that were reared at the Oklahoma State University, 
Centralized Tick Rearing Facility. The ticks were placed in 40 
an orthopedic stockinettes glued to the cow's side when A. 
marginale infection was observed in stained blood smears. 
The ticks were allowed to feed on cattle for seven days, after 
which they were removed and held in humidity for 5 days. 
The ticks were then allowed to feed for 7 days on a sheep to 45 
stimulate development of A. marginale into tick salivary 
glands. The ticks were then removed from the sheep and the 
salivary glands from 20 ticks (40 salivary glands) were 
dissected and pooled in 500 µl RNALater (Ambion). DNA 
was extracted from groups of 40 salivary glands and then 50 
used in a quantitative msp4 PCR to quantify A. marginale 
infection levels [19, 22]. 
3. Statistical Analysis 
For the analysis of the PPE and percent reduction PCV 
values between immunized and control cattle, pair wise 55 
comparisons (Student's t-test) were conducted. Salivary 
gland infection levels between ticks fed on vaccinated and 
control cattle were compared by Student's t-test. A correla-
tion analysis between tick salivary gland infection levels and 
antibody titers against MSPla in cattle during tick feeding 60 
was performed using Microsoft Excel 2000. 
4. Results 
12 
with the highest titers against MSPla were identified. Ten 
control animals were confirmed negative for MSPla anti-
bodies by Western blot. Mean peak PPE (3.6±2.6 and 
3.2±1.7 for control and immunized cattle, respectively) and 
mean percent reduction of PCVs (29.3±7 and 26.8±12.2 for 
control and immunized cattle, respectively) of immunized 
and control cattle during tick feeding were not significantly 
(P>0.05) (Table 4). 
TABLE 4 
Peak percent parasitized erythrocytes during tick feeding on cattle, 
anti-MSPla antibody titers, infection in tick salivary glands and inhibition 
of infection of A. marginale in ticks that acquired infection 
on immunized and control cattle. 
Tick 
infection 
Peak Anti- levels In-
PPE MSPla (copies hibition 
Experi- during anti- msp4/ of tick 
mental Cattle tick body salivary in-
groups numbera Immunogen feedingb titersc gland)" fectione 
Vac- GT 152 Recombinant 0.3 1600 0.1 100% 
cinated GT 155 MSPla 1.6 <100 14 93.5% 
GT 165 5.8 1600 80 62.6% 
219 4.5 200 2 99.1% 
248 3.2 800 14 93.5% 
141 IDES- 4.1 <100 25 88.3% 
GT 168 derived 1.6 <100 2 99.1% 
226 A. marginale 5.0 400 2 99.1% 
242 plus 3.0 400 14 93.5% 
294 recombinant 2.8 200 25 88.3% 
MSPla 
Control 143 None 4.3 <100 140 
157 0.5 100 0.4 
162 3.5 100 25 
166 2.5 <100 795 
210 3.2 100 2 
214 1.9 100 80 
217 1.6 100 140 
245 2.4 100 25 
247 6.9 400 140 
251 9.2 100 795 
'Cattle were analyzed for antibody response against recombinant MSPla 
before challenge-exposure. Ten immunized animals showing the highest 
titers against MSPla and 10 controls with sera negative for MSPla in the 
Western blot were selected. 
"The percent infected erythrocytes (PPE) was determined in blood smears 
of samples collected daily during the 7 days of tick acquisition-feeding. 
cvalues correspond to the maximum dilution that gave an OD450 nm equal 
or higher than mean background + 2 SD. 
ctDNA was extracted from 40 salivary glands and used in a quantitative 
PCR to determine A. marginale infection levels. The number of msp4 cop-
ies was calculated as 1o[(log Ta-O.S)/0.4]_ 
'The inhibition of tick infection was determined as [ 1 - (Infection level/ 
Mean control infection level)] x 100. 
Antibody titers against MSPla were determined by 
ELISA in sera obtained after tick infestation and compared 
between immunized and control cattle (Table 1). The aver-
age anti-MSPla antibody titers in immunized cattle 
(520±153; mean±SE) was higher (P=0.03) than in control 
cattle (110±34). 
A. marginale infection levels in salivary glands from ticks 
that fed on rickettsemic immunized and control cattle are 
listed in Table 1. Although infection levels varied among 
individual ticks, the number of msp4 copies per salivary 
gland was higher (P=0.04) in ticks fed on control cattle 
(214±98; mean±SE) when compared to ticks that fed on 
immunized cattle (18±8). Differences were not observed 
between ticks fed on cattle immunized with recombinant 
MSPla or with IDES-derived A. marginale together with 
Cattle chosen for these studies after vaccination and prior 
to challenge-exposure and tick feeding were based on high 
antibody titers to MSPla Serum samples collected two 
weeks after the last immunization were analyzed by Western 
blot for recognition of MSPla and 10 immunized animals 
65 recombinant MSPla. The average inhibition of tick infec-
tion in ticks that fed on the immunized cattle was 91.7% 
(range 62.69%-100.0%) (Table 4). 
US 6,979,451 Bl 
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Differences in infection rates between ticks that fed on 
immunized and control cattle did not appear to be affected 
by the A. marginale infections in cattle or the percent 
reduction PCVs during tick feeding. The PPEs in the cattle 
were not statistically different among groups and the percent 5 
reduction PCVs were not low enough to affect tick feeding. 
The results reported herein demonstrated that anti-MSPla 
antibodies in vaccinated cattle reduced infection of A. mar-
ginale for D. variabilis. Differences in salivary gland infec-
tion levels between ticks fed on immunized and control 10 
cattle agreed with statistically significant differences in the 
anti-MSPla antibody titers between immunized and control 
cattle after tick infestation. Difference in the results obtained 
after vaccination with recombinant MSPla compared to the 
antibody response generated after A. marginale infection of 15 
cattle could be explained by differences in the anti-MSPla 
antibody levels and/or by differences in the MSPla epitopes 
recognized by the antibodies. The recombinant MSPla 
protein is presented separately to the bovine immune 
system, rather than as a complex with MSPlb, which 20 
appears to allow for recognition of all the epitopes in the 
region containing the tandem repeats involved in adhesion 
of MSPla to tick cells [15]. The antibodies against the native 
MSPla may not be directed against the neutralizing domain 
masked by the structure of the MSPl complex. 25 
Comparison of the data obtained from cattle vaccinated 
with recombinant MSPla or with IDES-derived A. margi-
nale together with recombinant MSPla suggested that the 
antibody response against IDES and IDES-derived A. mar-
ginale antigens, other than MSPla, had little or no inhibitory 30 
effect on tick infection. The antibody response against 
MSPla inhibited but did not prevent infection of ticks by A. 
marginale. As was reported in previous studies [18, 36], 
salivary gland infection levels were variable and reflected 
variation among individual ticks. Although the effect on the 35 
transmission of A. marginale by ticks fed on vaccinated 
cattle is unknown, this study suggests that MSPla may be 
necessary but not sufficient for infection of ticks by A. 
marginale. Alternatively, over expression of MSPla in 
erythrocytic stages of A. marginale and/or the native struc- 40 
ture of MSPla may prevent the complete neutralization of 
the ligand. 
A desirable goal for a vaccine for the control of anaplas-
mosis is to have a protection effect on the multiplication of 
A. marginale in a bovine host and a blocking effect on the 45 
transmission of the pathogen by the tick vector. The results 
reported herein support the role of MSPla in the transmis-
sion of A. marginale by ticks and suggest the incorporation 
of recombinant MSPla in vaccine formulations against A. 
marginale in combination with infected IDF8 cells-derived 50 
antigens and/or as yet unidentified pathogen and tick-
derived antigens. 
While the invention has been been described with a 
certain degree of particularity, it is understood that the 
invention is not limited to the embodiment(s) set for herein 55 
for purposes of exemplification, but is to be limited only by 
the scope of the attached claim or claims, including the full 
range of equivalency to which each element thereof is 
entitled. 
Bibliography 
Each of the following publicly available documents is 
incorporated herein by reference. 
[1] Ristic, M. and A M. Watrach. 1963. Anaplasnosis. VI. 
60 
Studies and a hypothesis concerning the cycle of devel- 65 
opment of the causative agent. Am. J. Vet. Res. 
24:67-276. 
14 
[2] Kuttler, K. L. 1984. Anaplasma infections in wild and 
domestic ruminants: a review. J. Wild. Dis. 20:12-20. 
[3] Dikinans, G. 1950. The transmission of anaplasmosis. 
Am. J. Vet. Res. 11:5-16. 
[ 4] Ewing, S. A 1981. Transmission of Anaplasma margi-
nale by arthropods. In: Proc. 7th Nat Anaplasmosis Conf. 
Mississippi State University, MS, USA, pp. 395-423. 
[5] Kocan, K. M. 1986. Development of Anaplasma mar-
ginale: coordinated development of a rickettsial organ-
isms and its tick host. In: Sauer J R, Hair J A, editors. 
Morphology, Physiology and Behavioral Ecology of 
Ticks. Chichester: Horwood, pp.472-505. 
[6] Kocan, K. M., D. Stiller, W. L. Goff, P. L. Claypool, W. 
Edwards, S. A Ewing, T. C. McGuire, J. A Hair, and S. 
J. Barron. 1992. Development ofAnaplasma marginale in 
male Dermacentor andersoni transferred from infected to 
susceptible cattle. Am. J. Vet. Res. 53:499-507. 
[7] Ge, N. L., K. M. Kocan, E. F. Blouin, and G. L. Murphy. 
1996. Developmental studies of Anaplasma marginale 
(Rickettsiales: Anaplasmataceae) in male Dermacentor 
andersoni (Acari:Ixodidae) infected as adults using non-
radioactive in situ hybridization. J. Med. Ent. 33: 
911-920. 
[8] Kocan, K. M., W. L. Goff, D. Stiller, P. L. Claypool, W. 
Edwards, S. A Ewing, J. A Hair, and S. J. Barron. 1992. 
Persistence of Anaplasma marginale (Rickettsiales: 
Anaplasmataceae) in male Dermacentor andersoni 
(Acari: Ixodidae) transferred successively from infected 
to susceptible cattle. J. Med. Ent. 29:657-668. 
[9] Melendez RD, K. M. Kocan, A A Guglielmone and J. 
de la Fuente. 2002. Anaplasma marginale: Antigens and 
control alternatives for a rickettsial hemoparasite of cattle. 
Clin. Micro. Rev. Submitted June. 
[10] Palmer, G. H. 1989. Anaplasmosis vaccines, In: I G 
Wright, ed. Veterinary Protozoan and Hemoparasite Vac-
cines. Boca Raton (Fla.): CRC Press, pp. 1-29. 
[11] Allred, D.R., T. C. McGuire, G. H. Palmer, S. R. Leib, 
T. M. Harkins, T. F. McElwain and A F. Barbet. 1990. 
Molecular basis for surface antigen size polymorphisms 
and conservation of a neutralization-sensitive epitope in 
Anaplasma marginale. Proc. Nat. Acad. Sci. U.S.A. 
87:3220-3224. 
[12] Palmer, G. H., F. R. Rurangirwa, T. F. and T. F. 
McElwain. 2001. Strain composition of the ehrlichia 
Anaplasma marginale within persistently infected cattle, 
a mammalian reservoir for tick transmission J. Clin. 
Micro biol. 39: 631-635. 
[13] Bowie, M. V., J. de la Fuente, K. M. Kocan, E. F. 
Blouin, and A F. Barbet. 2001. Conservation of major 
surface protein 1 genes of the ehrlichial pathogen Ana-
plasma marginale during cyclic transmission between 
ticks and cattle. Gene 282:95-102. 
[14] de la Fuente, J., J.C. Garcia-Garcia, E. F. Blouin, S. D. 
Rodriguez, M. A Garcia, and K. M. Kocan. 2001a. 
Evolution and function of tandem repeats in the major 
surface protein la of the ehrlichial pathogen Anaplasma 
marginale. An. Health Res. Rev. 2:163-173. 
[15] de la Fuente, J., J. C. Garcia-Garcia, E. F. Blouin, and 
K. M. Kocan. 2002a. Characterization of the functional 
domain of major surface protein la involved in adhesion 
of the rickettsia Anaplasma marginale to host cells. Vet. 
Microbial. In press. 
[16] McGarey, D. J., A F. Barbet, G. H. Palmer, T. C. 
McGuire and D. R. Allred. 1994. Putative adhesins of 
Anaplasma marginale: major surface polypeptides la and 
lb. Infect. Immun. 62:4594-4601. 
[17] McGarey, D. J. amd D. R. Allred. 1994. Characteriza-
tion of hemagglutinating components on the Anaplasma 
US 6,979,451 Bl 
15 
marginale initial body surface and identification of pos-
sible adhesins. Infect. Immun. 62:4587-4593. 
[18] de la Fuente, J., J. C. Garcia-Garcia, E. F. Blouin, and 
K. M. Kocan. 2001b. Differential adhesion of major 
surface proteins la and lb of the ehrlichial cattle pathogen 5 
Anaplasma marginale to bovine erythrocytes and tick 
cells. Int. J. Parasitol. 31:145-153. 
[19] de la Fuente, J., J. C. Garcia-Garcia, E. F. Blouin and 
K. M. Kocan. (2001c). Major surface protein la effects 
tick infection and transmission of the ehrlichial pathogen 
10 Anaplasma marginale. Int. J. Parasitol. 31:1705-1714. 
[20] Kocan, K. M., T. Halbur, E. F. Blouin, V. Onet, J. de la 
Fuente, J. C. Garcia-Garcia and J. T. Saliki. 2001. Immu-
nization of cattle withAnaplasma marginale derived from 
tick cell culture. Vet. Parasitol. 102:151-161. 
[21] Brown, W. C., T. C. McGuire, D. Zhu, H. A Lewin, J. 15 
Sosnow, and G. H. Palmer. 2001. Highly conserved 
regions of the immunodominant major surface protein 2 
of the genogroup II ehrlichial pathogen Anaplasma mar-
ginale are rich in naturally derived CD4( +) T lymphocyte 
epitopes that elicit strong recall responses. J. Immunol. 20 
166:1114-1124. 
[22] de la Fuente, J., K. M. Kocan, J. C. Garcia-Garcia, E. 
F. Blouin, P. L. Claypool, P. L., J. T. Saliki. 2002b. 
Vaccination of cattle with Anaplasma marginale derived 
from tick cell culture and bovine erythrocytes followed by 25 
challenge-exposure by infected ticks. Vet. Microbial. 89: 
239-251. 
[23] Blouin, E. F., J. de la Fuente, J., J. C. Garcia-Garcia, J. 
16 
can isolates of Anaplasma marginale. Veterinary Parasi-
tology 2001; 97: 65-76. 
[33] Palmer G H, Waghela S D, Barbet AF, Davis W C, 
McGuire T C. Characterization of a neutralization-
sensitive epitope on the AM 105 surface protein of 
Anaplasma marginale. J Parasitol 1987; 17: 1279-1285. 
[34] Viseshakul N, Kamper S, Bowie M V, Barbet AF. 
Sequence and expression analysis of a surface antigen 
gene family of the rickettsiaAnaplasma marginale. Gene 
2000; 253: 45-53. 
[35] de la Fuente, J., Garcia-Garcia, J. C., Blouin, E. F., 
Kocan, K. M. Differential adhesion of major surface 
proteins la and lb of the ehrlichial cattle pathogen 
Anaplasma marginale to bovine erythrocytes and tick 
cells. Int. J. Parasitol. 2001; 31: 145-153. 
[36] Kocan K. M. and J. de la Fuente. 2002. Co-feeding 
studies of ticks infected with Anaplasma marginale. Vet. 
Parasitol. Submitted July. 
[37] Palmer G H, Barbet A F, Cantor G H, McGuire T C. 
Immunization of cattle with the MSP-1 surface protein 
complex induces protection against a structurally variant 
Anaplasma marginale isolate. Infect Immun 1989; 57: 
3666-3669. 
[ ] Kocan K M, Blouin E F, Barbet A F. Anaplasmosis 
control: past, present and future. Ann NY Acad Sci, 2000; 
916: 501-509. 
[ ] Barbet A F, Palmer G H, Myler P J, McGuire T C. 
Characterization of an immunoprotective protein complex 
ofAnaplasma marginale by cloning and expression of the 
gene coding for polypeptide AM 105L. Infect R. Sauer, J. T. Saliki, and K. M. Kocan. 2002a. Use of a 
cell culture system for studying the interaction of Ana-
plasma marginale with tick cells. Animal Health Res. 
Rev. In press. 
30 
Immun1987; 55: 2428-2435. 
[ ] McGarey D J, Allred D R. Characterization of hemag-
glutinating components on the Anaplasma marginale ini-
tial body surface and identification of possible adhesins. 
Infect Immun 1994; 62: 4587-4593. [24] Blouin, E. F., J. T. Saliki, J. de la Fuente, J. C. 
Garcia-Garcia, J. C. and K. M. Kocan. 2002b. Antibodies 
toAnaplasma marginale Major Surface Protein la and lb 35 
inhibit infectivity for cultured tick cells. Vet. Parasitol. 
(Submitted). 
[25] Brock, W. E., I. 0. Kliewer and C. C. Pearson. 1965. A 
vaccine for anaplasmosis. J. Am. Vet. Med. 
Assoc.147:943-951. 
[26] Palmer, G. H., S. D. Waghela, AF. Barbet, W. C. Davis 
and T. C. McGuire. 1987. Characterization of a neutral-
ization sensitive epitope on the AM 105 surface protein of 
Anaplasma marginale. J. Parasitol. 17:1279-1285. 
40 
[27] Hart, L. T., W. J. Todd and D. G Luther. 1990. 45 
Anaplasma marginale antigen, antigen composition, vac-
cine and process for production of said antigen, antigen 
composition and vaccine. U.S. Pat. No. 4,956,278. 
[28] Montenegro-James, S., M.A. James, M. Toro Benitez, 
E. Leon, B. K. Baek and A T. Guillen. 1991. Efficacy of 50 
purified Anaplasma marginale initial bodies as a vaccine 
against anaplasmosis. Parasitol. Res. 77:93-101. 
[29] McGarey DJ, Barbet AF, Palmer G H, McGuire TC, 
Allred D R. Putative adhesins of Anaplasma marginale: 
major surface polypeptides la and lb. Infect Immun 55 
1994; 62: 4594--4601. 
[30] Oberle S M, Palmer G H, Barbet AF, McGuire T C. 
Molecular size variations in an immunoprotective protein 
complex among isolates of Anaplasma marginale. Infect 
Immun 1988; 56:1567-1573. 60 
[31] Allred D R, McGuire T C, Palmer G H, Leib S R, 
Harkins T M, McElwain T F, Barbet AF. Molecular basis 
for surface antigen size polymorphisms and conservation 
of a neutralization-sensitive epitope in Anaplasma mar-
ginale. Proc Natl Acad Sci USA 1990; 87: 3220---3224. 65 
[32] de la Fuente, J., van den Bussche, R. A., Kocan, K. M. 
Molecular phylogeny and biogeography of North Ameri-
[ ] Munderloh U G, Blouin E F, Kocan K M, Ge N L. 
Establishment of the tick (Acari: Ixodidae )-borne cattle 
pathogen Anaplasma marginale (Rickettsiales: 
Anaplasmataceae) in tick cell culture. J Med Ent 1996; 
33: 656-664. 
[ ] Blouin E F, Barbet AF, Jooyoung Yi, Kocan K M, Saliki 
J T. Establishment and characterization of an Oklahoma 
isolate ofAnaplasma marginale in cultured Ixodes scapu-
laris cells. Vet Parasitol 1999; 87: 301-313. 
[ ] Blouin E F, Kocan K M. Morphology and development 
of Anaplasma marginale (Rickettsiales: 
Anaplasmataceae) in cultured Ixodes scapularis (Acari: 
Ixodidae) cells. J Med Entomol 1998; 35: 788-797. 
[ ] Barbet AF, Blentlinger R, Jooyoung Yi, Lundgren AM, 
Blouin E F, Kocan K M. Comparison of surface proteins 
of Anaplasma marginale grown in tick cell culture, tick 
salivary glands, and cattle. Infect Immun1999; 67: 
102-107. 
[] Barbet, AF., R. Blentlinger, J. Yi, AM. Lundgren, E. F. 
Blouin, and K. M. Kocan. 1999. Comparison of surface 
proteins of Anaplasma marginale grown in tick cell 
culture, tick salivary glands, and cattle. Infect. Immun. 
67:102-107. 
[ ] Eid, G., D. M. French, A M. Lundgren, A F. Barbet, T. 
F. McElwain, and G. H. Palmer. 1996. Expression of 
major surface protein 2 antigenic variants during acute 
Anaplasma marginale rickettsemia. Infect. Immun. 
64:836-841. 
[ ] Kocan K. M., E. F. Blouin G. H. Palmer, I. S. Eriks and 
W. L. Edwards. 1996. Preliminary studies on the effect of 
Anaplasma marginale antibodies ingested by Dermacen-
tor andersoni ticks (Acari: Ixodidae) with their bloodmeal 
on infections in salivary glands. Exp. Appl. Acarol. 
20:297-311. 
17 
<160> NUMBER OF SEQ ID NOS: 10 
<210> SEQ ID NO 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
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SEQUENCE LISTING 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 1 
gcattacaac gcaacgcttg ag 
<210> SEQ ID NO 2 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 2 
gctttacgcc gccgcctgcg cc 
<210> SEQ ID NO 3 
<211> LENGTH: 30 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 3 
ccgctcgaga tgttagcgga gtatgtgtcc 
<210> SEQ ID NO 4 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 4 
gaagatctcg ccgccgcctg cgcc 
<210> SEQ ID NO 5 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 5 
ccgaattcca tgttagcggc taattggcgg caagagatgc g 
<210> SEQ ID NO 6 
<211> LENGTH: 29 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 6 
ccagatctct ttacgccgcc gcctgcgcc 
<210> SEQ ID NO 7 
<211> LENGTH: 27 
18 
22 
22 
30 
24 
41 
29 
19 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
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<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 7 
gagatctgct gatggctcgt cagcggg 
<210> SEQ ID NO 8 
<211> LENGTH: 31 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 8 
ggtcgaccct gattgagacg atgtactggc c 
<210> SEQ ID NO 9 
<211> LENGTH: 2154 
<212> TYPE: DNA 
<213> ORGANISM: Anaplasma marginale 
<400> SEQUENCE: 9 
27 
31 
gcattacaac gcaacgcttg agtgatgttt acggctgtag tattgtgctt atggcagaca 60 
tttccatata ctgtgcagta cggttgtgct ccccaattgt taaaatttag tatattaatc 120 
ttgcgattac acgttccgta tgttacaatc aggccgccgg tgtggtagcg tgctggttgt 180 
gtggttgtcc tctttcccga tgttgggtcg ttcgttttac gtcgcacaag tttgtacgct 240 
gtgcccctgg cagtgtaggg tttatttgtt tgtgtgtgtg ttatgttagc ggagtatgtg 300 
tccccccagc cagctgatgg ctcgtcagcg ggtggtcagc agcaagagag tagtgtgtca 360 
tctcaaagtg atcaggccag tacatcgtct caattaggag ctgatagctc gtcagcgggt 420 
ggtcagcagc aagagagtag tgtgtcatct caaagtggtc aggccagtac atcgtctcaa 480 
ttagggactg atagctcgtc agcgagtggt cagcagcaag agagtagtgt gtcatctcaa 540 
agtggtcagg ccagtacatc gtctcaatca ggagctaatt ggcggcaaga gatgcgctcc 600 
aaggttgcga gtgttgagta cattttggct gctcgtgccc ttatttctgt aggggtctat 660 
gctgctcagg gagagatcgc gaaatcgcaa gggtgtgctc ccctgcgtgt tgcagaagtc 720 
gaagaaatcg tgagggatgg ccttgtacgc agccactttc atgatagtgg cctttcacta 780 
ggctccatac gactcgtgct tatgcaggtt ggggataagt tggggctaca aggtttgaag 840 
attggcgaag ggtacgccac ctatctcgcg caagcgtttg ctgacaacgt ggtggttgcg 900 
gctgatgttc aaagtggtgg tgcgtgctct gccagccttg acagcgcgat cgcaaacgtt 960 
gagacgtcgt ggtccctgca cggcggcctg gtaagcaaag attttgaccg tgataccaaa 1020 
gtagaaaggg gcgaccttga ggcttttgtc gacttcatgt ttggcggtgt gtcgtacaat 1080 
gatgggaacg cgtctgcggc taggagcgta ttggaaacgc ttgccgggca cgtcgatgca 1140 
cttggtatat cgtacaatca gctggataag cttgatgctg acactttgta tagtgtcgta 1200 
tcgtttagtg ccggttccgc aatagacaga ggtgcggtta gcgatgcggc tgacaagttc 1260 
cgtgtgatga tgtttggtgg tgctcctgcg gggcaagaga aaactgccga acctgagcat 1320 
gaggctgcga ccccgtcagc tagtagcgtt ccgtcaactg tgcatggtaa ggtcgttgat 1380 
gcagttgacc gtgcaaaaga agcggctaag caggcctatg caggcgtgcg taagcggtat 1440 
gtggcgaagc cttcggacac tactacacag cttgttgtag ctatcacggc gctgcttatc 1500 
20 
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-continued 
acggcgtttg ctatctgtgc 
atttggggct gcctggcact 
gcagtgagtg cttcgagtca 
gagaggtcta gggaattgtc 
gcgatactga ccgggttgag 
gttgacgcga ggcgcgggac 
tttgcgatca gtgccgctgt 
gatagcaagt gtgctacagc 
cgtgctaccg agggcgttgt 
acttccgtgc cgtcagccgg 
gatccacaac ttgttgctac 
<210> SEQ ID NO 10 
<211> LENGTH: 623 
<212> TYPE: PRT 
gtgtttggaa cctaggctta 
agtagcactg ctgccattac 
aaagaaggct gccggtggtg 
ccgtgcgaga caggaagatc 
cgtgcttgtg tttattgctg 
gtggcagggc agcatatgtt 
tgtaatggca acacgtgacc 
tcgtacggct caagctgtac 
tagcggtggc agccaagaag 
gtctgggtcc gtacctcctg 
tttgggagca ggtgtggcgc 
<213> ORGANISM: Anaplasma marginale 
<400> SEQUENCE: 10 
taggggcgtc cggtccgctg 
ttggtatggc tgtgcatacg 
cgcaacgggt tgctgctcag 
agcagaagtt gcatgttccc 
ccgtcgtggc ttgtattgct 
tcctagccgc atttgtgttg 
aatcgttggc agaagagtgt 
ccggtggcca gcagcagccg 
gcggggctgg tgttcccgga 
ctaccattat ggtcagtgtg 
aggcggcggc gtaa 
Met Leu Ala Glu Tyr Val Ser Pro Gln Pro Ala Asp Gly Ser Ser Ala 
1 5 10 15 
Gly Gly Gln Gln Gln Glu Ser Ser Val Ser Ser Gln Ser Asp Gln Ala 
20 25 30 
Ser Thr Ser Ser Gln Leu Gly Ala Asp Ser Ser Ser Ala Gly Gly Gln 
35 40 45 
Gln Gln Glu Ser Ser Val Ser Ser Gln Ser Gly Gln Ala Ser Thr Ser 
50 55 60 
Ser Gln Leu Gly Thr Asp Ser Ser Ser Ala Ser Gly Gln Gln Gln Glu 
65 70 75 80 
Ser Ser Val Ser Ser Gln Ser Gly Gln Ala Ser Thr Ser Ser Gln Ser 
85 90 95 
Gly Ala Asn Trp Arg Gln Glu Met Arg Ser Lys Val Ala Ser Val Glu 
100 105 110 
Tyr Ile Leu Ala Ala Arg Ala Leu Ile Ser Val Gly Val Tyr Ala Ala 
115 120 125 
Gln Gly Glu Ile Ala Lys Ser Gln Gly Cys Ala Pro Leu Arg Val Ala 
130 135 140 
Glu Val Glu Glu Ile Val Arg Asp Gly Leu Val Arg Ser His Phe His 
145 150 155 160 
Asp Ser Gly Leu Ser Leu Gly Ser Ile Arg Leu Val Leu Met Gln Val 
165 170 175 
Gly Asp Lys Leu Gly Leu Gln Gly Leu Lys Ile Gly Glu Gly Tyr Ala 
180 185 190 
Thr Tyr Leu Ala Gln Ala Phe Ala Asp Asn Val Val Val Ala Ala Asp 
195 200 205 
Val Gln Ser Gly Gly Ala Cys Ser Ala Ser Leu Asp Ser Ala Ile Ala 
210 215 220 
Asn Val Glu Thr Ser Trp Ser Leu His Gly Gly Leu Val Ser Lys Asp 
225 230 235 240 
Phe Asp Arg Asp Thr Lys Val Glu Arg Gly Asp Leu Glu Ala Phe Val 
245 250 255 
Asp Phe Met Phe Gly Gly Val Ser Tyr Asn Asp Gly Asn Ala Ser Ala 
22 
1560 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
2100 
2154 
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-continued 
260 265 270 
Ala Arg Ser Val Leu Glu Thr Leu Ala Gly His Val Asp Ala Leu Gly 
275 280 285 
Ile Ser Tyr Asn Gln Leu Asp Lys Leu Asp Ala Asp Thr Leu Tyr Ser 
290 295 300 
Val Val Ser Phe Ser Ala Gly Ser Ala Ile Asp Arg Gly Ala Val Ser 
305 310 315 320 
Asp Ala Ala Asp Lys Phe Arg Val Met Met Phe Gly Gly Ala Pro Ala 
325 330 335 
Gly Gln Glu Lys Thr Ala Glu Pro Glu His Glu Ala Ala Thr Pro Ser 
340 345 350 
Ala Ser Ser Val Pro Ser Thr Val His Gly Lys Val Val Asp Ala Val 
355 360 365 
Asp Arg Ala Lys Glu Ala Ala Lys Gln Ala Tyr Ala Gly Val Arg Lys 
370 375 380 
Arg Tyr Val Ala Lys Pro Ser Asp Thr Thr Thr Gln Leu Val Val Ala 
385 390 395 400 
Ile Thr Ala Leu Leu Ile Thr Ala Phe Ala Ile Cys Ala Cys Leu Glu 
405 410 415 
Pro Arg Leu Ile Gly Ala Ser Gly Pro Leu Ile Trp Gly Cys Leu Ala 
420 425 430 
Leu Val Ala Leu Leu Pro Leu Leu Gly Met Ala Val His Thr Ala Val 
435 440 445 
Ser Ala Ser Ser Gln Lys Lys Ala Ala Gly Gly Ala Gln Arg Val Ala 
450 455 460 
Ala Gln Glu Arg Ser Arg Glu Leu Ser Arg Ala Arg Gln Glu Asp Gln 
465 470 475 480 
Gln Lys Leu His Val Pro Ala Ile Leu Thr Gly Leu Ser Val Leu Val 
485 490 495 
Phe Ile Ala Ala Val Val Ala Cys Ile Ala Val Asp Ala Arg Arg Gly 
500 505 510 
Thr Trp Gln Gly Ser Ile Cys Phe Leu Ala Ala Phe Val Leu Phe Ala 
515 520 525 
Ile Ser Ala Ala Val Val Met Ala Thr Arg Asp Gln Ser Leu Ala Glu 
530 535 540 
Glu Cys Asp Ser Lys Cys Ala Thr Ala Arg Thr Ala Gln Ala Val Pro 
545 550 555 560 
Gly Gly Gln Gln Gln Pro Arg Ala Thr Glu Gly Val Val Ser Gly Gly 
565 570 575 
Ser Gln Glu Gly Gly Ala Gly Val Pro Gly Thr Ser Val Pro Ser Ala 
580 585 590 
Gly Ser Gly Ser Val Pro Pro Ala Thr Ile Met Val Ser Val Asp Pro 
595 600 605 
Gln Leu Val Ala Thr Leu Gly Ala Gly Val Ala Gln Ala Ala Ala 
610 615 620 
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What is claimed is: 
26 
4. The method according to claim 3, wherein said tick cell 
culture comprises Ixodes scapularis tick cell line IDES. 
5. The method according to claim 1, wherein said recom-
binant MSPla is from the Oklahoma isolate of A. marginale. 
6. The method according to claim 3, wherein said tick cell 
culture derived A. marginale, is selected from the group 
consisting of the Oklahoma, Virginia and Oregon isolates of 
A. marginale. 
1. A method for reducing A. marginale infection in ticks, 
said method comprising: administering to a ruminant popu-
lation susceptible to tick infection a composition comprising 
recombinant MSPla and an immunogen derived from A. s 
marginale; wherein said immunogen is not MSPlb and said 
composition further comprises a pharmaceutically accept-
able carrier or diluent; and allowing said ticks to feed on said 
ruminants. 
2. The method according to claim 1, wherein approxi-
mately 100 µg of said recombinant MSPla is administered. 
3. The method according to claim 1, wherein said immu-
nogen is tick cell culture derived A. marginale. 
7. The method according to claim 3, wherein said com-10 
position contains approximately 2xl010 A. marginale. 
* * * * * 
